Epidemiology and histopathological classification of lung cancer: A study from Jordan, retrospective observational study

Alqudah, Mohammad; Alfaqih, Mahmoud A.; Hamouri, Shadi; Al-Shaikh, Ala’a; Haddad, Husam K.; Al-Quran, Wejdan Y.; Alebbini, Mohanad M; Amer, Nama' Bany; AL-Smadi, Haifa I.; Alzoubi, Karem H.

doi:10.1016/j.amsu.2021.102330

Cited by 2 publications

(1 citation statement)

References 20 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In males, it is the second most prevalent type of cancer and the primary cause of cancer-related mortality, accounting for 22.4% of all cancer deaths among men ( 1 ). The smoking prevalence in Jordan reaches up to 51% ( 2 ) and the average age for lung cancer diagnosis was reported as 63.8 years ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan

Abu Hejleh,

AlSawalha,

Abdel Hafiz

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThis study aims to evaluate real-world (rw) outcomes of immunotherapy (IO) for advanced stage NSCLC at King Hussein Cancer Center (KHCC) in Jordan.MethodsAdvanced stage NSCLC patients who received IO at KHCC between 2017 and 2022 were included. The data were retrospectively collected. PFS and OS were estimated for patients with ECOG performance status (ECOG PS) 0-1. Cox regression analyzed predictors of OS in first-line (1L) IO, regardless of performance status.ResultsThe total number of patients included was 244. Out of those, 160 (65%), 67 (28%), and 17 (7%) patients received IO as 1L, second-line (2L), or third-line or beyond (3L or beyond), respectively. The median age for all patients was 59 years. Male were 88%, and 77% were smokers. The median follow-up time was 12.5 months. The median PFS and OS for 1L IO were 7 [95% CI 5.8 – 10.3] and 11.8 [95% CI 8.8 – 14.4], months, respectively. In the first 3 months after starting 1L IO, 34/160 (21%) patients had died. For those who survived beyond 3 months after starting 1L IO, the median PFS and OS were 11.3 [95% CI 8.3 – 16.5] and 15.4 [95% CI 13.2 – 21] months, respectively. In the Cox regression model of 1L IO patients with any performance status, ECOG PS 2 was predictive of worse OS compared to ECOG PS 0-1 (p= 0.005).ConclusionThis real-world study of advanced-stage NSCLC patients treated with immunotherapy at KHCC reveals outcomes that fall short of those anticipated from clinical trials. The inclusion of Middle Eastern patients in lung cancer trials is essential to ensure adequate representation of various ethnicities in clinical research.

show abstract

Section: Introductionmentioning

confidence: 99%

Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan

Abu Hejleh,

AlSawalha,

Abdel Hafiz

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients

Abu Al Karsaneh,

Al Anber,

ALQudah

et al. 2023

Diagn Pathol

View full text Add to dashboard Cite

Background Human epidermal growth factor receptor 2 (HER2), a promising therapeutic target, can be mutated, amplified, or overexpressed in different malignancies, including non-small cell lung cancer (NSCLC). Although these alterations showed adverse prognostic effects in many cancers, their clinical significance in NSCLC is controversial. This study primarily assessed the prevalence of HER2 protein expression in NSCLC among Jordanian patients. In addition, the possible association between HER2 protein expression and clinicopathological variables was evaluated. Methods A total of 100 surgically resected NSCLC cases treated at King Hussein Cancer Center (KHCC) between 2009 and 2021 were examined for HER2 protein expression using immunohistochemistry (IHC). The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines for breast cancer were applied to interpret the results with a final score ranging from 0 to 3+, considering a score of 3 + as overexpression. Additionally, a separate subset of patients was tested for HER2 gene mutation. Fisher’s exact test was used to assess the association between HER2 scores and the other variables. Kaplan-Meier method was used to calculate survival. Results Of the 100 cases, Her2 overexpression (score 3+) was detected in 2 cases (2%), score 2 + in 10 cases (10%), score 1 + in 12 cases (12%), and score 0 in 76 cases (76%). The two positive cases were one adenocarcinoma and one squamous cell carcinoma; both patients were elderly male smokers. No significant association was identified between Her2 expression and age, gender, smoking, histological subtype, grade, stage, tumor size, and lymph node status. Our findings also showed no association between Her2 expression and survival; however, advanced tumor stages and positive lymph node metastasis were significantly associated with poor overall survival. All cases tested for the Her2 mutation were negative. Conclusions Her2 overexpression is uncommon in NSCLC among the Jordanian population. However, when the same scoring criteria are used, the rates are similar to other results found in Asian cohorts. Due to our study’s relatively small sample size, a larger one is required to investigate the prognostic value and the molecular associations between the different Her2 alterations.

show abstract

Epidemiology and histopathological classification of lung cancer: A study from Jordan, retrospective observational study

Cited by 2 publications

References 20 publications

Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan

Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan

Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients

Contact Info

Product

Resources

About